Subscribe To
AFMD / Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings
AFMD News
By GlobeNewsWire
November 1, 2023
Affimed to Participate in Upcoming Investor Conferences
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncolog more_horizontal
By Zacks Investment Research
October 25, 2023
Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal
By GlobeNewsWire
September 21, 2023
Affimed to Present at the Cantor Global Healthcare Conference 2023
MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncol more_horizontal
By GlobeNewsWire
September 7, 2023
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving pati more_horizontal
By InvestorPlace
August 23, 2023
Surprise! These 3 Penny Stocks Have Wall Street's Seal of Approval.
Although relative few investors – let alone analysts hired by top research institutions – give much thought to low-volume speculative securities, more_horizontal
By Zacks Investment Research
August 10, 2023
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
Affimed N.V. (AFMD) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. more_horizontal
By InvestorPlace
August 4, 2023
3 Cheap Stocks to Buy Under $1 in August 2023
The world of penny stocks is rife with potential pitfalls to avoid. Many firms trading at those prices are manipulated by actors with bad intent. more_horizontal
By GlobeNewsWire
August 3, 2023
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patie more_horizontal